AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
18 oct. 2023 09h00 HE
|
AVITA Medical
AVITA Medical announces third quarter 2023 preliminary commercial revenue of $13.5 million and secures up to $90 million of non-dilutive debt financing.
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
25 sept. 2023 08h00 HE
|
AVITA Medical
VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical to Present at the Cantor Global Healthcare Conference
21 sept. 2023 16h30 HE
|
AVITA Medical
VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical to Participate in Upcoming Investor Conferences
06 sept. 2023 18h45 HE
|
AVITA Medical
VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical to Host Investor Webinar Briefing
14 août 2023 08h00 HE
|
AVITA Medical
VALENCIA, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical Reports Second Quarter Financial Results
10 août 2023 16h01 HE
|
AVITA Medical
VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of...
AVITA Medical to Announce Second Quarter 2023 Financial Results
20 juil. 2023 16h05 HE
|
AVITA Medical
VALENCIA, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical Submits FDA PMA Supplement for RECELL GO
29 juin 2023 18h21 HE
|
AVITA Medical
VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class...
AVITA Medical Rejoins the Russell 3000 Index
26 juin 2023 08h00 HE
|
AVITA Medical
VALENCIA, Calif., and MELBOURNE, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
16 juin 2023 14h47 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...